This material is suppliedΒ exclusively as a laboratory research chemicalΒ forΒ in vitro scientific study. All descriptions and are providedΒ for informational and educational purposes only.
This compound isΒ not approvedΒ for human or animal consumption, injection, ingestion, inhalation, topical use, or any other biological application. It must be handled only by qualified, trained personnel in a properly equipped laboratory.
This product isΒ notΒ a drug, supplement, food, cosmetic, or therapeutic agent, and it may not be rebranded, repackaged, or marketed as any such item.Β Misuse, mislabeling, or unauthorized application is strictly prohibited.
Nothing on this website constitutes medical advice, professional guidance, or a recommendation of use.
(Dual GLP-1 / Glucagon Receptor Agonist; Peptide Research Compound)
Survodutide is a synthetic peptide designed to act as a co-agonist at both the glucagon receptor (GCGR) and glucagon-like peptide-1 receptor (GLP-1R).
Both receptors are class B GPCRs primarily coupled to Gs, producing adenylyl cyclase activation β cAMP accumulation β PKA signaling, alongside secondary ERK1/2 and PI3K-Akt cascades.
Ligand binding causes:
GsΞ± activation β adenylyl cyclase
β cAMP
PKA activation
CREB phosphorylation
Gene transcription changes in metabolic tissues
Activation leads to:
Adenylyl cyclase β cAMP β
Regulation of glycogen metabolism enzymes
Secondary contributions from Gq/PLC/IPβ in select cell systems
cAMP accumulation activates PKA
PKA phosphorylates CREB
CREB binds cAMP-response elements (CREs) on metabolic and mitochondrial genes
Representative CREB-responsive targets:
PPARGC1A (PGC-1Ξ±)
NRF1, TFAM (mitochondrial biogenesis)
SLC2A4 (GLUT4)
PDK4
Triggered downstream of GLP-1R signaling:
PI3K activation β Akt phosphorylation
Influences transcription of metabolic and stress-response genes
Measured targets in research systems:
FOXO1, GSK-3Ξ², SREBP-1c
BCL2, MCL1 (mitochondrial survival signaling)
Both GCGR and GLP-1R can signal through:
Ras β Raf β MEK β ERK1/2
ERK nuclear translocation β immediate-early gene expression
ERK-responsive genes:
FOS, JUN, EGR1
CCND1 (cell-cycle progression)
| Component | Role in Survodutide Signaling |
|---|---|
| cAMP β | Central second messenger for both receptors |
| PKA | Phosphorylates CREB, ion channels, metabolic enzymes |
| CREB | Drives transcription of mitochondrial and metabolic genes |
| ERK1/2 | Mitogenic and transcriptional responses |
| CaΒ²βΊ | Can be elevated via GCGR-linked PLC/IPβ pathways |
Survodutide signaling influences expression/activity of:
Glycogen synthase (GYS)
Glycogen phosphorylase (PYGL/PYGM)
CPT1, ACADL, PGC-1Ξ±
SLC2A4 (GLUT4)
CD36
FABP family
| Category | Example Genes |
|---|---|
| cAMP/CREB Axis | CREB1, NR4A1, PPARGC1A (PGC-1Ξ±) |
| Mitochondrial Biogenesis | NRF1, TFAM, COX genes |
| Glucose & Lipid Metabolism | SLC2A4 (GLUT4), CPT1B, ACADL, PDK4 |
| MAPK-Responsive | FOS, JUN, EGR1, CCND1 |
| Cell Survival / Stress | BCL2, MCL1, SOD2 |
Dual GLP-1R and GCGR agonist
Activates Gs β adenylyl cyclase β cAMP β PKA β CREB
Secondary activation of ERK1/2 and PI3K/Akt
Drives transcription of metabolic, mitochondrial, and immediate-early genes in model systems
Survodutide is supplied exclusively for in-vitro laboratory research.
Not approved for human or animal administration, therapeutic use, or any biological application outside controlled research environments.
| Weight | N/A |
|---|---|
| Size | 10 Mg |
